Shanghai Labway Clinical Laboratory Co., Ltd.

Shenzhen Stock Exchange 301060.SZ

Shanghai Labway Clinical Laboratory Co., Ltd. Price to Sales Ratio (P/S) on January 27, 2025: 2.08

Shanghai Labway Clinical Laboratory Co., Ltd. Price to Sales Ratio (P/S) is 2.08 on January 27, 2025, a -19.46% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Shanghai Labway Clinical Laboratory Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 3.30 on March 21, 2024, which is 58.74% above the current Price to Sales Ratio (P/S).
Shanghai Labway Clinical Laboratory Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 1.75 on July 24, 2024, which is -15.66% below the current Price to Sales Ratio (P/S).
Shanghai Labway Clinical Laboratory Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 2.28.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shenzhen Stock Exchange: 301060.SZ

Shanghai Labway Clinical Laboratory Co., Ltd.

CEO	Mr. Weixiong Zeng
IPO Date	Sept. 13, 2021
Location	China
Headquarters	Building 1, Lane 268
Employees	1,487
Sector	Healthcare
Industries Biotechnology Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Hardware & Electronics Personal Care Professional Services Specialty Retail

Description

Shanghai Labway Clinical Laboratory Co., Ltd. offers sales services for in vitro diagnostic products; and medical laboratory services. Shanghai Labway Clinical Laboratory Co., Ltd. was founded in 1993 and is based in Shanghai, China.

Key trends

Past 5 years